Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis

This study has been completed.
Information provided by (Responsible Party):
ALK-Abelló A/S Identifier:
First received: April 2, 2006
Last updated: February 7, 2013
Last verified: February 2013

April 2, 2006
February 7, 2013
April 2006
May 2009   (final data collection date for primary outcome measure)
Changes from baseline in SCORAD and topical medication consumption [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Sccore of atopic dermatitis (SCORAD)
Recording of symptoms and medication
Complete list of historical versions of study NCT00310492 on Archive Site
Changes from baseline in SCORAD intensity score, EASI score and change in topical medication consumption [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Eczema Area Severity Index (EASI)
Quality of life and adverse events
SCORAD extent criteria, index, subjective symptoms, IGA score, oral rescue medication, exacerbation of atopic dermatitis, DLQI, treatment expectation questionnaire [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Investigator´s Global Assessment (IGA), Dermatology Life Quality Index (DLQI)
Not Provided
Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis
Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study to Demonstrate the Efficacy of a 12-month Subcutaneous Specific Immunotherapy With ALK-depot SQ Milbenmischung in Patients With Atopic Dermatitis and Proven IgE-mediated Sensitization to House Dust Mites

This trial is performed to assess the efficacy and safety of ALK-depot SQ mites for treatment of atopic dermatitis

Not Provided
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Atopic Dermatitis
Biological: subcutaneous immunotherapy
Updosing by 16 injections to 100,000 SQ-U
Other Name: ALK-depot SQ mites
  • Active Comparator: Subcutaneous immunotherapy
    Subcutaneous injections with ALK-depot SQ mites to 100,000 SQ-U
    Intervention: Biological: subcutaneous immunotherapy
  • Placebo Comparator: Subcutaneous injections
    placebo injections
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2009
May 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Positive specific IgE to house dust mites
  • Atopic dermatitis according to Hanifin/Rajka
  • Chronic course of Atopic dermatitis
  • SCORAD larger than 25 points

Exclusion Criteria:

  • Erythrodermia
  • Syst.treatment with gcs or immunosuppressive agents in the prev.4 weeks
  • History of specific immunotherapy with mites
  • UV radiation
  • Group 4 topical corticosteroids (European classification)
18 Years to 55 Years
Contact information is only displayed when the study is recruiting subjects
ALK-Abelló A/S
ALK-Abelló A/S
Not Provided
Study Director: Hendrik Wolf, PhD ALK-SCHERAX Arzneimittel GmbH
Principal Investigator: Alexander Kapp, MD, Prof. Hannover Medical School
ALK-Abelló A/S
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP